Zhuo Shenghua, Chen Zhimin, Yang Yibei, Zhang Jinben, Tang Jianming, Yang Kun
Department of Neurosurgery, First Affiliated Hospital of Hainan Medical College, Haikou, China.
State Key Laboratory of Oncogenes and Related Genes, Renji-Med-X Clinical Stem Cell Research Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Front Oncol. 2020 Nov 20;10:590861. doi: 10.3389/fonc.2020.590861. eCollection 2020.
Ferroptosis is a form of cell death characterized by non-apoptosis induced by small molecules in tumors. Studies have demonstrated that ferroptosis regulates the biological behaviors of tumors. Therefore, genes that control ferroptosis can be a promising candidate bioindicator in tumor therapy. Herein, functions of ferroptosis-related genes in glioma were investigated. We systematically assessed the relationship between ferroptosis-related genes expression profiles and prognosis in glioma patients based on The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) RNA sequencing datasets. Using the non-negative matrix factorization (NMF) clustering method, 84 ferroptosis-related genes in the RNA sequencing data were distinctly classified into two subgroups (named cluster 1 and cluster 2) in glioma. The least absolute shrinkage and selection operator (LASSO) was used to develop a 25 gene risk signature. The relationship between the gene risk signature and clinical features in glioma was characterized. Results show that the gene risk signature associated with clinical features can be as an independent prognostic indicator in glioma patients. Collectively, the ferroptosis-related risk signature presented in this study can potentially predict the outcome of glioma patients.
铁死亡是一种细胞死亡形式,其特征是由肿瘤中的小分子诱导的非凋亡过程。研究表明,铁死亡调节肿瘤的生物学行为。因此,控制铁死亡的基因可能成为肿瘤治疗中有前景的候选生物标志物。在此,我们研究了铁死亡相关基因在胶质瘤中的功能。我们基于癌症基因组图谱(TCGA)和中国胶质瘤基因组图谱(CGGA)RNA测序数据集,系统评估了铁死亡相关基因表达谱与胶质瘤患者预后之间的关系。使用非负矩阵分解(NMF)聚类方法,将RNA测序数据中的84个铁死亡相关基因在胶质瘤中明确分为两个亚组(命名为簇1和簇2)。使用最小绝对收缩和选择算子(LASSO)构建了一个包含25个基因的风险特征。对该基因风险特征与胶质瘤临床特征之间的关系进行了表征。结果表明,与临床特征相关的基因风险特征可作为胶质瘤患者的独立预后指标。总体而言,本研究中呈现的铁死亡相关风险特征可能预测胶质瘤患者的预后。